Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

tDCS sosiaalisen median riippuvuuden hoitoon (tDCS4SMA)

maanantai 2. marraskuuta 2026 päivittänyt: Egas Moniz - Cooperativa de Ensino Superior, CRL

Ei-invasiivisen neuromodulaation vaikutus sosiaalisen median riippuvuuteen

The goal of this clinical trial is to learn whether transcranial direct current stimulation (tDCS), a non-invasive brain stimulation, can reduce "craving" and problematic levels of social media/internet use in university students.

The main questions it aims to answer are:

  • Does active tDCS reduce craving to use social media during the intervention period compared with sham stimulation and no stimulation?
  • Does active tDCS reduce internet/social media addiction severity (measured with the Internet Addiction Test, IAT) compared with sham stimulation and no stimulation, and are any effects still present at follow-up? Researchers will compare three groups-active tDCS, sham tDCS (a simulation where stimulation is stopped after the first seconds), and a control group (no stimulation)-to see whether changes are due to tDCS rather than placebo effects or time.

Participants will:

  • Complete an initial screening and baseline questionnaires (a sociodemographic questionnaire and the IAT).
  • Be randomly assigned to one of three groups: active tDCS, sham tDCS, or control (no stimulation).
  • Complete the IAT again after the intervention and again about 5 weeks later (follow-up), along with questions about social media use habits.

During intervention, participants in active tDCS and sham tDCS will:

  • Attend 10 sessions over 2 consecutive weeks (Monday-Friday), with each session lasting about 30 minutes; mobile phone use is not allowed during sessions.
  • Rate craving on a Visual Analogue Scale (VAS) at the start and end of each session.

This study will be conducted with university students in the Greater Lisbon area and will follow double-blind procedures for the active vs sham conditions (participants and researchers will not know the assigned condition until the end of the study).

Tutkimuksen yleiskatsaus

Tila

Valmis

Ehdot

Interventio / Hoito

Yksityiskohtainen kuvaus

This study investigates whether non-invasive neuromodulation using transcranial direct current stimulation (tDCS) can reduce craving and problematic social media/internet use in university students. The rationale for the study is that excessive and compulsive social media use has been associated with negative mental health outcomes, and behavioral addictions may share neurobiological features with substance addictions, including reward-circuit involvement and reduced inhibitory control. Because tDCS can modulate cortical excitability, often targeting prefrontal areas involved in executive control, this project evaluates whether repeated tDCS sessions can help reduce craving and improve digital self-regulation in individuals with moderate-to-severe problematic use.

Study design and setting The study uses an experimental, double-blind design to strengthen internal validity by reducing expectation and observer bias. Recruitment and data collection will be carried out with university students from the Greater Lisbon area, and study activities will take place in a controlled setting with supervision by the research team. The study is planned as a quantitative, applied primary research project.

Participants and eligibility criteria The sample will be non-probabilistic and recruited by convenience among university students in the Greater Lisbon area. Eligible participants must be 18 years of age or older, available for all study phases, and score 31 or higher on the Internet Addiction Test (IAT), indicating moderate-to-severe dependence.

Participants will be excluded if they have had recent psychopharmacological changes (use or dose change within the last 3 months), a history of dizziness or seizures, a current need for hospitalization or psychotherapy, or diagnoses such as depressive, anxiety, or bipolar disorders with recent symptoms, schizophrenia, other psychotic disorders, or autism spectrum disorder. Additional exclusions include contraindications to tDCS, such as pregnancy, metallic implants, tumors, prior brain surgery, or significant anatomical brain changes.

Recruitment and informed consent Recruitment will occur through in-person informational sessions, where study objectives will be presented and a QR code will be provided for enrollment. Outreach will also be supported through social media and flyers in institutions in the Greater Lisbon area. Interested individuals will provide informed consent and complete an initial sociodemographic questionnaire and the IAT as part of screening/baseline assessment.

Group allocation and masking After recruitment, participants will be randomly allocated to one of three groups: (1) active tDCS, (2) sham stimulation, or (3) control without stimulation, and then contacted via email. The sham condition is designed to mimic the sensation of stimulation to help control for placebo effects. Double-blinding will be implemented for the active vs sham conditions, with coded accounts ("real" and "sham") created to ensure the research team does not know condition assignments until the study ends. The control group does not receive stimulation.

Intervention (tDCS) and device The intervention consists of 10 consecutive sessions delivered over two weeks (Monday to Friday), with each session lasting approximately 30 minutes and following recommended safety parameters. Sessions will be supervised by the research team in a controlled environment, and mobile phone use will be prohibited during sessions.

Stimulation will be delivered using the PlatoWork tDCS Headset, a certified non-invasive neuromodulation device, controlled through the PlatoApp, which guides positioning and helps prevent configuration errors. Electrode positioning will follow the International 10/20 system, with the anode placed at F4 (right dorsolateral prefrontal cortex) and the cathode at F3 (left dorsolateral prefrontal cortex).

Measures and outcomes Data will be collected using a sociodemographic questionnaire, the Internet Addiction Test (IAT), and a Visual Analogue Scale (VAS) for craving. The sociodemographic questionnaire will be used to characterize the sample and verify inclusion/exclusion criteria, including variables such as age, sex, psychotropic medication use, pregnancy status, recent therapies, psychological diagnoses, and presence of metallic implants; it also includes questions on social media habits (daily time, frequency, and typical moments of use).

The IAT is a 20-item self-report Likert-scale measure (0-5), with a total score ranging from 0 to 100; higher scores indicate greater dependence/problematic use. Craving will be measured with a VAS consisting of a 10 cm line anchored from 0 (no desire) to 10 (extremely strong desire).

Craving (VAS) will be assessed twice per stimulation session: at the beginning of each session (baseline craving for that session) and at the end of each session (post-stimulation craving). The IAT and social media habit questions will be administered again after the intervention period and again at follow-up approximately five weeks later to evaluate potential cumulative and sustained effects.

Study procedure and timeline After baseline screening and enrollment, participants will attend the intervention period (10 sessions across two weeks) according to their assigned group (active tDCS, sham, or control). Participants in the stimulation arms will complete craving ratings at the start and end of each session. After the two-week intervention, participants will repeat the IAT and usage-habit questions. Five weeks after the intervention, participants will complete follow-up measures (IAT and usage-habit questions). After completion of the study, a debriefing will be conducted, and participants in the sham and control groups may be offered the real tDCS protocol.

Data management and statistical analysis Data will be extracted from the instruments, organized in digital databases, and analyzed using IBM SPSS Statistics (version 30), with procedures to ensure anonymization and confidentiality. Each participant will be identified only by a numeric code. Analyses will compare changes in craving and dependence across three time points (pre, post, and follow-up) and across groups (active, sham, control).

A repeated-measures MANOVA is planned to test group effects, time effects, and group × time interactions across dependent variables, followed by univariate repeated-measures ANOVAs and post-hoc tests with correction for multiple comparisons when appropriate. The significance level will be set at p < .05.

Ethical considerations and participant safety Participation will be voluntary, and all participants will receive clear information about study objectives, procedures, risks, benefits, and data handling before providing written informed consent. Participants may refuse or withdraw at any time without consequences and may request deletion of their data at any stage.

All data will be pseudonymized using numeric codes, and the code-key linking identities to study codes will be stored separately in an encrypted, password-protected file accessible only to the research team. Data will be stored in a secure institutional digital environment (OneDrive). The PlatoApp associated with the PlatoWork headset does not collect personal information; it records only technical session data (e.g., date, time, duration, intensity) without individual identification.

tDCS is described as a safe and non-invasive technique with typically mild, temporary side effects such as tingling, mild skin discomfort, or mild headache; any adverse effects will be recorded and evaluated, and medical referral may be arranged if needed. Equipment will be sanitized between uses, and conductive sponges will be dedicated to each participant. Participants showing signs of emotional or psychological fragility may be advised to discontinue and may be referred for psychological support at the university psychology clinic.

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

61

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

      • Almada, Portugali
        • Egas Moniz School of Health and Science

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Age ≥18 years.
  • Availability to participate in all study phases/sessions.
  • IAT score ≥31 (moderate to severe level).

Exclusion Criteria:

  • Diagnosis of depressive, anxiety, or bipolar disorders with recent symptoms; schizophrenia; psychotic disorders; or autism spectrum disorder.
  • Recent psychotropic medication use or dose change within the last 3 months.
  • Current need for inpatient care or ongoing psychotherapy.
  • History of dizziness or seizures/convulsions.
  • Contraindications to tDCS, including pregnancy, metallic implants, tumors, prior brain surgery, or significant anatomical brain alterations.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Perustiede
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Kolminkertaistaa

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Active tDCS

Participants receive active transcranial direct current stimulation (tDCS) delivered in 10 consecutive sessions (Monday-Friday for 2 weeks), 30 minutes per session, under supervision in a controlled setting. Electrode placement follows the International 10/20 system with the anode at F4 (right DLPFC) and the cathode at F3 (left DLPFC). Craving is rated before and after each session using a Visual Analogue Scale (VAS).

Active tDCS delivered in 10 consecutive sessions (Monday-Friday over 2 weeks), 30 minutes per session, in a supervised controlled environment. Electrode montage follows the International 10/20 system with the anode at F4 (right dorsolateral prefrontal cortex) and the cathode at F3 (left dorsolateral prefrontal cortex).

Muut nimet:
  • (tDCS)
Huijausvertailija: Sham tDCS

Participants undergo the same schedule and procedures as the experimental arm (10 sessions over 2 weeks; 30 minutes/session; supervised; same electrode placement), but stimulation is discontinued after the first seconds to simulate stimulation while minimizing neuromodulatory effects.

Sham stimulation using the same device setup and schedule as active tDCS, but the stimulation is turned off after the first seconds to mimic the sensation while minimizing neuromodulatory effects. Sessions are supervised, with the same electrode positioning (anode F4; cathode F3).

Muut nimet:
  • (Feikki-tDCS)
  • Simuloitu tDCS
Ei väliintuloa: No Stimulation Control

Participants do not receive tDCS sessions (no stimulation intervention). They complete the study assessments, including the Internet Addiction Test (IAT) and questions about social media use habits at baseline and post-intervention, with follow-up reassessment approximately 5 weeks later.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in Internet Addiction Test (IAT) Total Score
Aikaikkuna: Baseline (pre-intervention); immediately post-intervention (after the 10-session/2-week period); follow-up ~5 weeks after the intervention.

Severity of problematic internet/social media use measured by the Internet Addiction Test (IAT; 20 items; total score 0-100, higher scores mean worse outcome). The IAT is administered at baseline (pre-intervention), after completion of the intervention period, and again at follow-up to evaluate sustained effects. Group comparisons will be made between active tDCS, sham, and control arms.

Baseline (pre-intervention); immediately post-intervention (after the 10-session/2-week period); follow-up ~5 weeks after the intervention.

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in Social Media Craving (VAS)
Aikaikkuna: Each of 10 sessions over 2 consecutive weeks: assessed immediately pre-session and immediately post-session.

A Visual Analogue Scale (VAS) to assess Craving to social media . The VAS is administered twice per tDCS session: at the start of the session (pre) and at the end of the session (post). Participants are asked to rate their desire to use social media from 0 to 10, higher scores mean worse outcome.

Each of 10 sessions over 2 consecutive weeks: assessed immediately pre-session and immediately post-session.
Change in Social Media Use Habits (Self-Report)
Aikaikkuna: Baseline (pre-intervention); immediately post-intervention; follow-up ~5 weeks after the intervention.

Self-reported social media use habits collected via the study's questionnaire items (e.g., daily time, frequency, and typical moments of access). These items are used to characterize patterns of use and to assess changes over time following the intervention.

Baseline (pre-intervention); immediately post-intervention; follow-up ~5 weeks after the intervention.

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Yleiset julkaisut

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Sunnuntai 1. maaliskuuta 2026

Ensisijainen valmistuminen (Todellinen)

Perjantai 31. heinäkuuta 2026

Opintojen valmistuminen (Todellinen)

Maanantai 2. marraskuuta 2026

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Lauantai 7. helmikuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Lauantai 7. helmikuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Perjantai 13. helmikuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Keskiviikko 4. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 2. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. helmikuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • PT-213/25

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

PÄÄTTÄMÄTÖN

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .